Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma/Prostat Adenokarsinomunda Caveolin-1 ve PSA'nin Karsilastirilmasi

Citation metadata

Authors: Ozkan Onuk, Baris Nuhoglu, Arif Ozkan, Tuncay Tas, Nusret Can Cilesiz and Aydin Ismet Hazar
Date: Dec. 2019
From: Journal of Academic Research in Medicine(Vol. 9, Issue 3)
Publisher: AVES
Document Type: Report
Length: 3,482 words

Main content

Abstract :

Objective: The aim of the present study was to evaluate caveolin-1 (CAV-1) levels as a possible alternative for the prostate specific antigen in the diagnosis of patients with prostate adenocarcinoma (PCa). Methods: The study was conducted with 33 cases (mean age 67.2 (45-90) years) and 16 control patients (mean age 56.68 (48-77) years). Blood sample solution results of both the groups were read twice, and the average optical density of the zero standard was subtracted from the solution results' average. Results: The average levels of prostate-specific antigen (PSA) were 1.1 ([+ or -]0.64) for the control group and 12.3 ([+ or -]8.7) for patients with adenocarcinoma. The average levels of CAV-1 were 336 ([+ or -]41.1) in the control group and 476 ([+ or -]66.9) in patients with adenocarcinoma. PCa was detected in 33 patients, 27 of whom underwent prostatectomy, and the remaining 6 began hormonotherapy. Of these 33 patients, 2 had a Gleason score of 4, 16 had a Gleason score of 6, 10 had a Gleason score of 7, 3 had a Gleason score of 8, and 2 had a Gleason score of 9. Patients with PCa had higher PSA and CAV-1 than the control group (p 0.05). Conclusion: The level of CAV-1 was found to be higher in patients with PCa. CAV-1 can be used as an alternative for PSA, but it is not superior to PSA with respect to diagnosis, cost, and testing difficulty. In spite of the challenges its examination presents, CAV-1 is a protein, which should be tested in areas, such as early diagnosis, active surveillance, hormone refractory PCa, and radical prostatectomy. Keywords: Caveolin, prostate carcinoma, PSA, prostate-specific antigen Amac: Bu calismanin amaci prostat adenokarsinomu (PCa) olan hastalarin tanisinda prostat spesifik antijen (PSA) icin olasi bir alternatif olarak Caveolin-1 (CAV-1) seviyelerini degerlendirmektir. Yontemler: Calisma 33 hasta ve 16 kontrol grubu olmak uzere iki gruba ayrilmistir. Her iki grubun kan orneklerinden ELISA kiti ile CAV-1 duzeyleri calisildi. Sonuclar tani oncesi PSA duzeyi ile karsilastirilarak istatistiksel olarak analiz edildi. Bulgular: Calismada hasta grubunun yas ortalamasi 67,2 (45-90) iken kontrol grubunu ortalama yasi 56,68 (48-77) idi. PSA ortalamasi kontrol grubu icin 1,1 ([+ or -]0,64), adenokarsinomali hastalar icin 12,3 ([+ or -]8,7) idi. Kontrol grubunda ortalama CAV-1 duzeyi 336 ([+ or -]41,1), adenokarsinomali hastalarda ise 476 ([+ or -]66,9) idi. Hastalarin 27'sine prostatektomi yapildi, geriye kalan 6'sina ise hormonoterapiye baslandi. Bu 33 hastadan 18'inin Gleason Skoru (GS) 6 ve altinda, 10'u GS 7, 3'unun GS 8 ve 2'si GS 9 idi. Prostat adenokarsinomu olan grupta daha yuksek PSA ve CAV-1 duzeyleri saptandi (p 0,05). Sonuc: Prostat adenokarsinomu olan hastalarda CAV-1 degeri daha yuksek bulundu. Prostat kanseri tanisi icin yeni bir belirtec olarak kullanilabilir. Ancak tani, maliyet ve test zorlugu dusunuldugunde PSA'dan ustun degildir. CAV-1 erken tani, aktif surveyans, hormon refrakter PCa ve radikal prostatektomi gibi alanlarda test edilmesi gereken bir proteindir. Anahtar kelimeler: Caveolin, PSA, prostat spesifik antijen, prostat kanseri

Source Citation

Source Citation
Onuk, Ozkan, et al. "Comparison of Caveolin-1 and PSA in Prostate Adenocarcinoma/Prostat Adenokarsinomunda Caveolin-1 ve PSA'nin Karsilastirilmasi." Journal of Academic Research in Medicine, vol. 9, no. 3, 2019, p. 121+. Accessed 8 Mar. 2021.
  

Gale Document Number: GALE|A581865886